Healthcare
ALK-Abelló A/S(AKBLF)
Live Price
Offline$40.65
+0.00% today
1Y Change
+47.02%
Window
Jun 25, 2025 → Jun 19, 2026
- Market Cap
- $56.37B
- Revenue Growth
- +13.7%
- EPS Growth
- +47.0%
- Dividend Yield
- 0.6%
Coverage: 255 bars · Jun 25, 2025 → Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ALK-Abelló A/S (AKBLF) is a Healthcare stock with a market cap of $56.37B and listed on OTC. The stock last traded around $40.65 and up 47.0% across the available one-year price window (Jun 25, 2025 → Jun 19, 2026). Baseline metrics include revenue growth of +13.7%, EPS growth of +47.0%, a dividend yield of 0.6%. What stands out right now is revenue +13.7%, EPS +47.0%, free cash flow +1808.3% with operating margin 26.2% and ROIC 15.3%. The dividend is present but secondary, with a yield around 0.6%. Valuation already assumes a fairly strong business story at P/E 47.1 and price/sales 8.9. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines AKBLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+13.7% vs +7.6% peer median
Operating Margin
Above sector median
+26.2% vs +19.4% peer median
P/E
Above sector median
47.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +13.7% and EPS at +47.0%, with operating margin around 26.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 0.6%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Δ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | — | +0.0% | +0.0% | +9.4% |
2026 Feb 20, 2026 | -7.7% | +0.0% | +0.0% | -10.9% |
2025 Nov 12, 2025 | +40.2% | +5.1% | +4.8% | +9.4% |
Benchmark Edge
AKBLF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
AKBLF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
AKBLF Max Drawdown
-13.26%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for AKBLF and SPY.
Company Overview
ALK-Abelló A/S
Other OTC
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. It also provides adrenaline auto-injectors for the treatment of severe allergic reactions; and manufactures products used in the diagnosis of allergies. The company offers GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.
- Leadership
- Peter Halling
- IPO Date
- Nov 16, 2009
- Employees
- 2.7k
- Street Address
- Boge Alle 6-8
- Mailing
- Horsholm, 2970
- Region
- Horsholm, DK
- Reporting Currency
- USD
- Investor Line
- 45 45 74 75 76
- Last Updated
- May 6, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 47.1
- EV/EBITDA
- 28.1
- Price/Sales
- 8.9
- Price/Book
- 8.7
Growth
- Revenue
- +13.7%
- EPS
- +47.0%
- Free Cash Flow
- +1808.3%
Profitability
- Gross Margin
- 67.1%
- Operating Margin
- 26.2%
- Net Margin
- 19.0%
- ROE
- 19.8%
- ROIC
- 15.3%
Balance Sheet
- Debt/Equity
- 0.10
- Current Ratio
- 3.38
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.